KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $79.1 million.

  • Bionano Genomics' Liabilities and Shareholders Equity fell 950.07% to $79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $310.2 million, marking a year-over-year decrease of 4735.31%. This contributed to the annual value of $76.7 million for FY2024, which is 6424.04% down from last year.
  • As of Q3 2025, Bionano Genomics' Liabilities and Shareholders Equity stood at $79.1 million, which was down 950.07% from $76.0 million recorded in Q2 2025.
  • In the past 5 years, Bionano Genomics' Liabilities and Shareholders Equity ranged from a high of $384.9 million in Q1 2021 and a low of $76.0 million during Q2 2025
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $271.4 million (2023), whereas its average is $232.8 million.
  • As far as peak fluctuations go, Bionano Genomics' Liabilities and Shareholders Equity soared by 191476.81% in 2021, and later tumbled by 6424.04% in 2024.
  • Bionano Genomics' Liabilities and Shareholders Equity (Quarter) stood at $377.1 million in 2021, then decreased by 18.46% to $307.5 million in 2022, then crashed by 30.28% to $214.4 million in 2023, then plummeted by 64.24% to $76.7 million in 2024, then increased by 3.12% to $79.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $79.1 million for Q3 2025, versus $76.0 million for Q2 2025 and $78.4 million for Q1 2025.